• Astellas Pharma Europe BV, of Meppel, The Netherlands, a subsidiary of Astellas Pharma Inc., reported the Dutch Medicines Evaluation Board granted marketing authorization for Vesomni (solifenacin + tamsulosin) in the Netherlands. The once-daily treatment is for moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia in men who are not adequately responding to treatment with monotherapy.

• Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA Peripheral and Central Nervous System Drugs Advisory Committee voted in favor of the firm's low-dose sleep aid, suvorexant, to treat insomnia. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with insomnia. It was developed to block the action of orexins, neurotransmitters in a specific part of the brain that help to keep a person awake. By temporarily blocking the actions of orexins, suvorexant helps to facilitate sleep. Merck anticipates FDA action on suvorexant by midyear.

• Perrigo Co., of Allegan, Mich., is transferring the listing of its U.S.-traded common stock to the New York Stock Exchange (NYSE) from Nasdaq. The company expects to begin trading on the NYSE on June 6 under its current stock symbol "PRGO," and will continue to trade on Nasdaq until the transfer takes place.